The Fundamental Problem: Dogs Experience Pain But Cannot Quantify It
Pain management in dogs operates under a fundamental constraint: the patient cannot tell you where it hurts, how much it hurts, or whether the treatment is working. Dogs mask pain as an evolutionary survival strategy. Owners underestimate pain severity in up to 50% of cases. Even trained veterinarians show significant inter-rater variability when scoring pain using behavioral assessment tools (Epstein et al., 2015).
This assessment gap has real consequences for canine longevity. Chronic undertreated pain from arthritis, dental disease, cancer, and other conditions reduces quality of life, limits physical activity (accelerating deconditioning and muscle loss), elevates stress hormones that promote inflammatory aging, and may shorten lifespan through cumulative physiological burden.
The search for objective pain biomarkers — measurable biological indicators that correlate with pain intensity independent of behavioral observation — is one of the most important frontiers in veterinary medicine.
Current Behavioral Assessment: The Best We Have, But Not Good Enough
The Canine Brief Pain Inventory (CBPI) developed by Brown et al. (2007) is the most validated owner-reported pain instrument for dogs with osteoarthritis. The Glasgow Composite Pain Scale (GCPS) is the standard for acute pain assessment in clinical settings. The Helsinki Chronic Pain Index adds validated chronic pain measurement.
These tools represent significant advances over unstructured assessment, but they share inherent limitations:
- They measure behavior, not pain directly
- They are influenced by the observer’s experience, emotional state, and expectations
- They miss stoic dogs who suppress pain behaviors
- They cannot distinguish pain intensity from pain tolerance
- They may conflate pain with anxiety, fear, or cognitive dysfunction
Substance P
Substance P is a neuropeptide released by sensory neurons in response to noxious stimuli. It is a key mediator of pain transmission in the dorsal horn of the spinal cord and has been studied as a potential pain biomarker in multiple species.
In dogs, cerebrospinal fluid (CSF) substance P levels have been measured in dogs with osteoarthritis, intervertebral disc disease, and syringomyelia. Elevated CSF substance P correlates with clinical pain scores in some studies, supporting its role as a pain biomarker. However, CSF collection requires anesthesia and lumbar puncture, making it impractical for routine clinical monitoring.
Serum substance P is easier to measure but has shown inconsistent correlation with pain in published veterinary studies. The discrepancy likely reflects the fact that substance P in the periphery serves multiple functions beyond pain signaling, including immune modulation and vasodilation.
Nerve Growth Factor (NGF)
Nerve growth factor has emerged as one of the most promising pain biomarkers in veterinary research. NGF is upregulated in inflamed tissues, sensitizes nociceptors (pain-detecting neurons), and drives the transition from acute to chronic pain.
Knazovicky et al. (2016) demonstrated that dogs with naturally occurring osteoarthritis show widespread somatosensory sensitivity — increased pain response to pressure not just at the affected joint but at remote body sites — consistent with central sensitization. This central sensitization process is mediated in part by NGF, and serum NGF levels correlate with the degree of somatosensory change.
The therapeutic relevance is direct: monoclonal antibodies targeting NGF (anti-NGF therapy) have been developed for dogs. Beransa (bedinvetmab), a canine anti-NGF monoclonal antibody, was approved for osteoarthritis pain management in dogs. Its mechanism validates NGF as both a pain mediator and a monitoring target.
Cortisol and Stress Hormones
Cortisol elevation is a non-specific but measurable response to pain. Salivary cortisol is non-invasively collectible and has been used in veterinary pain research:
- Post-surgical cortisol levels correlate with pain scores in dogs recovering from orthopedic surgery
- Chronic pain conditions show less consistent cortisol elevation, possibly due to hypothalamic-pituitary-adrenal axis adaptation
- Cortisol measurements are confounded by stress, excitement, and circadian variation, requiring standardized collection protocols
Rialland et al. (2012) used cortisol alongside behavioral scoring to assess visceral pain in dogs, finding that cortisol added predictive value beyond behavioral assessment alone but was not sufficiently specific to serve as a standalone pain marker.
Inflammatory Cytokines
Pro-inflammatory cytokines — IL-6, TNF-alpha, IL-1beta — are elevated in inflammatory pain states and can be measured in serum, synovial fluid, and saliva:
- Synovial fluid cytokine profiles correlate with articular pain severity and predict response to anti-inflammatory treatment
- Serum cytokine panels may detect systemic inflammatory pain burden that physical examination underestimates
- The relationship between cytokine levels and pain is not linear; some dogs with high inflammatory markers report low pain scores, and vice versa
Emerging Technologies
Quantitative Sensory Testing (QST)
QST applies standardized mechanical, thermal, or electrical stimuli and measures the threshold at which the dog responds. Von Frey filaments (mechanical threshold), thermal probes (heat/cold threshold), and pressure algometry provide quantitative, repeatable pain sensitivity measurements. QST is used in research settings to document:
- Central sensitization (lowered pain thresholds at sites remote from injury)
- Treatment response (threshold improvement after analgesic administration)
- Breed-specific pain sensitivity differences
Gait Analysis
Force plate and pressure-sensitive walkway analysis objectively measure lameness through ground reaction forces, stance time, and weight distribution. This technology detects lameness that is imperceptible to human observation and quantifies improvement from analgesic interventions with high precision.
Facial Coding
The Dog Grimace Scale adapts the human Facial Action Coding System to identify facial expressions associated with acute pain. Orbital tightening, muzzle tension, ear position, and cheek muscle activation provide species-specific pain indicators. Inter-rater reliability data is promising but the tool requires further validation across breeds with different facial morphology.
Where We Are and Where We Are Going
No single biomarker currently provides a reliable, non-invasive, specific measure of pain intensity in dogs. The most promising approach is multi-modal: combining serum NGF, inflammatory cytokine panels, cortisol, validated behavioral scoring, and objective functional measures (activity tracking, gait analysis) into a composite pain index that is more accurate than any individual component.
For owners managing a dog with chronic pain, the practical takeaway is to use multiple assessment methods: validated pain scales, activity monitoring, periodic veterinary reassessment with consistent scoring, and objective outcome tracking when possible. Single data points are unreliable; trends over time are informative.
Frequently Asked Questions
Why do we need objective pain biomarkers for dogs?
Dogs cannot self-report pain intensity, and behavioral assessment — while the current clinical standard — is subjective and varies by observer. Objective pain biomarkers could provide quantifiable, repeatable measurements that detect pain earlier, monitor treatment response more accurately, and reduce the systematic undertreatment of pain that results from dogs’ evolutionary tendency to hide discomfort.
What biomarkers are being studied for measuring pain in dogs?
The most studied biomarkers include Substance P (a neuropeptide elevated in chronic pain states), nerve growth factor (NGF, elevated in arthritic joints), cortisol and cortisol metabolites (stress-related), and inflammatory cytokines (IL-6, TNF-alpha). Emerging technologies include gait analysis sensors, facial expression recognition algorithms, and electroencephalography (EEG) for measuring pain-related brain activity.
Is there currently a blood test that can measure pain in dogs?
No clinically validated blood test exists for pain measurement in dogs as of 2026. While research has identified blood biomarkers that correlate with pain states, none have been validated for routine clinical use. The challenge is distinguishing pain-specific biomarker changes from changes caused by inflammation, stress, or underlying disease.
How far away is objective pain measurement for dogs?
The field is advancing but reliable clinical tools are likely 5-10 years away. Wearable activity monitors already provide indirect pain assessment (dogs in pain move less), and AI-based behavioral analysis is progressing rapidly. A validated point-of-care pain biomarker would be transformative for veterinary medicine but requires extensive clinical validation before adoption.
Bottom Line
No single biomarker currently provides a reliable, non-invasive measure of pain intensity in dogs, but nerve growth factor and inflammatory cytokine panels show the most promise as objective pain indicators. The most accurate approach combines validated behavioral scales, activity monitoring, periodic veterinary assessment, and — when available — quantitative sensory testing or gait analysis. For owners managing chronic pain, tracking multiple data points over time is more informative than any single measurement, and undertreated pain has real consequences for longevity through its effects on muscle mass, mobility, and chronic stress.
References
- Epstein ME et al. AAHA/AAFP pain management guidelines for dogs and cats (Journal of the American Animal Hospital Association, 2015).
- Knazovicky D et al. Widespread somatosensory sensitivity in naturally occurring canine model of osteoarthritis (Pain, 2016).
- Rialland P et al. Assessing experimental visceral pain in dogs: a pilot study (Journal of Veterinary Internal Medicine, 2012).
- Brown DC et al. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis (American Journal of Veterinary Research, 2007).